JP2011157397A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157397A5
JP2011157397A5 JP2011108837A JP2011108837A JP2011157397A5 JP 2011157397 A5 JP2011157397 A5 JP 2011157397A5 JP 2011108837 A JP2011108837 A JP 2011108837A JP 2011108837 A JP2011108837 A JP 2011108837A JP 2011157397 A5 JP2011157397 A5 JP 2011157397A5
Authority
JP
Japan
Prior art keywords
seq
pta
cancer
igf1r
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011108837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157397A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157397A publication Critical patent/JP2011157397A/ja
Publication of JP2011157397A5 publication Critical patent/JP2011157397A5/ja
Pending legal-status Critical Current

Links

JP2011108837A 2004-12-03 2011-05-13 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー Pending JP2011157397A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63315604P 2004-12-03 2004-12-03
US60/633,156 2004-12-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007544441A Division JP2008521907A (ja) 2004-12-03 2005-11-30 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011280276A Division JP2012067124A (ja) 2004-12-03 2011-12-21 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Publications (2)

Publication Number Publication Date
JP2011157397A JP2011157397A (ja) 2011-08-18
JP2011157397A5 true JP2011157397A5 (https=) 2012-02-16

Family

ID=36190453

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007544441A Withdrawn JP2008521907A (ja) 2004-12-03 2005-11-30 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
JP2011108837A Pending JP2011157397A (ja) 2004-12-03 2011-05-13 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
JP2011280276A Pending JP2012067124A (ja) 2004-12-03 2011-12-21 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007544441A Withdrawn JP2008521907A (ja) 2004-12-03 2005-11-30 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011280276A Pending JP2012067124A (ja) 2004-12-03 2011-12-21 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Country Status (11)

Country Link
US (1) US7811562B2 (https=)
EP (3) EP1828249B1 (https=)
JP (3) JP2008521907A (https=)
AT (1) ATE493442T1 (https=)
CA (1) CA2589885A1 (https=)
DE (1) DE602005025685D1 (https=)
ES (1) ES2356830T3 (https=)
MX (1) MX2007006640A (https=)
PT (1) PT1828249E (https=)
TW (1) TWI376233B (https=)
WO (1) WO2006060419A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP3211093A1 (en) 2005-04-14 2017-08-30 The Trustees of Boston University Diagnostic for lung disorders using class prediction
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
CA2623125A1 (en) * 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
WO2007093008A1 (en) * 2006-02-17 2007-08-23 Adelaide Research & Innovation Pty Ltd Antibodies to insulin-like growth factor i receptor
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
US20100120055A1 (en) * 2006-09-28 2010-05-13 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2104501B1 (en) * 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
EP2559771A3 (en) * 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CA2694990A1 (en) * 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CN101990577A (zh) * 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
JP2010540960A (ja) * 2007-10-03 2010-12-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
WO2009045389A2 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2011505873A (ja) * 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
SG2014006860A (en) * 2008-11-12 2014-05-29 Merck Sharp & Dohme ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
JP2012519170A (ja) * 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011052749A1 (ja) 2009-10-30 2011-05-05 学校法人慶應義塾 抗がん剤の感受性の判定方法
EP2494070A2 (en) * 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
EP3260859B1 (en) 2009-12-22 2020-02-05 Expression Pathology, Inc. Inuslin receptor substrate 1 (irs1) protein srm/mrm assay
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2595657A4 (en) * 2010-07-22 2015-09-23 Univ California ANTI-TUMOR ANTIGEN ANTIBODIES AND USE PROCESSES
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2766497A1 (en) * 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3268038B1 (en) 2015-03-09 2021-05-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
WO2017197335A1 (en) 2016-05-12 2017-11-16 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
CN121754667A (zh) * 2020-04-08 2026-03-31 阿里亚达治疗公司 用于血脑屏障递送的组合物和方法
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
TW202519262A (zh) * 2023-09-06 2025-05-16 美商維里迪恩醫療股份有限公司 抗ｉｇｆ－１ｒ抗體之醫藥組合物

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4543439A (en) * 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5262308A (en) * 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ATE191853T1 (de) * 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
WO1994023034A2 (en) * 1993-04-06 1994-10-13 Cedars-Sinai Medical Center Variant insulin-like growth factor i receptor subunits and methods for use thereof
US20020022023A1 (en) * 1999-01-15 2002-02-21 Axel Ullrich Treatment of diabetes mellitus and insulin receptor signal transduction
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US6084085A (en) * 1995-11-14 2000-07-04 Thomas Jefferson University Inducing resistance to tumor growth with soluble IGF-1 receptor
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
US20020107187A1 (en) * 1996-05-22 2002-08-08 Kingston David J. Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US20020155095A1 (en) * 1996-10-18 2002-10-24 Tattanahalli L. Nagabhushan Methods and compositions for delivery and expression of interferon-a nucleic acids
BR9712362A (pt) 1996-10-18 1999-08-31 Canji Inc Métodos e composições para distribuição e expressão de ácidos nucléicos de alfa-interferon
AU5451598A (en) 1996-11-22 1998-06-10 Regents Of The University Of California, The Transport of liposomes across the blood-brain barrier
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE19719001C2 (de) 1997-05-06 2001-05-10 Schuetzdeller Angelika Verfahren zum immunologisch-funktionalen Nachweis biologisch aktiver Insulin-Like Growth Factor Binding Proteine oder löslicher Insulin-Like Growth Factor - Rezeptoren im Immunoassay
IL136114A0 (en) 1997-11-14 2001-05-20 Euro Celtique Sa Immunoglobulin molecules having a synthetic variable region and modified specificity
US7020563B1 (en) 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
EP1064015A2 (en) 1998-02-24 2001-01-03 Receptron, Inc. Receptor derived peptides as modulators of receptor activity
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
WO2000050067A1 (en) 1999-02-26 2000-08-31 Saltech I Göteborg Ab Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
AU6607100A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU1410801A (en) 1999-11-17 2001-05-30 Compugen Ltd. Variants of alternative splicing
AU2135001A (en) * 1999-12-15 2001-06-25 Mcgill University Targeting of endosomal growth factor processing as anti-cancer therapy
WO2001070930A2 (en) 2000-03-21 2001-09-27 University Of South Florida Growth factor binding molecules
EP1265635A1 (en) 2000-03-22 2002-12-18 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1383793B1 (en) 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
AU5521401A (en) 2000-03-31 2001-10-15 Hyseq Inc Method and materials relating to insulin-like growth factor binding protein-likepolypeptides and polynucleotides
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7329745B2 (en) * 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
IL153853A0 (en) 2000-07-10 2003-07-31 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US20020048550A1 (en) 2000-07-20 2002-04-25 Vallera Daniel A. Radiolabeled immunotoxins
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
DE10050338A1 (de) 2000-10-11 2002-04-25 Deutsches Krebsforsch Auf dem Nachweis von IGF-IRbeta und IRS-1 beruhendes Diagnose- bzw. Klassifizierungsverfahren für Carcinome
MXPA03003207A (es) * 2000-10-12 2004-03-26 Icos Corp Materiales y metodos para modular la actividad de union de ligando/enzimatica de proteinas alfa/¦ que contienen un sitio regulador alosterico.
EP1332368A2 (en) * 2000-11-03 2003-08-06 Board of Regents, The University of Texas System Methods for detecting the efficacy of anticancer treatments
MXPA03004913A (es) 2000-12-01 2003-09-05 Schering Corp Usos de genes de mamifero y reactivos relacionados.
WO2002054066A2 (en) 2000-12-14 2002-07-11 The Burnham Institute Non-apoptotic forms of cell death and methods of modulation
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
DK1395669T3 (da) * 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
WO2002072780A2 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
FR2824076B1 (fr) 2001-04-27 2003-06-13 Centre Nat Rech Scient Methode de detection de composes activateurs ou inhibiteurs des recepteurs de la famille du recepteur de l'insuline au moyen d'un recepteur chimere isole
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
CA2445898A1 (en) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20050037445A1 (en) 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation
IL160091A0 (en) 2001-08-06 2004-06-20 Stil Biotechnologies Ltd Methods of identifying functional analogs of peptide regulators of biological pathways
AUPR870501A0 (en) 2001-11-07 2001-11-29 Biotech Research Ventures Pte Limited Composition containing a flavonoid glycone and method for using same as anti-proliferative
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
FR2834900B1 (fr) 2002-01-18 2005-07-01 Pf Medicament Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
SI1461359T1 (sl) 2002-01-18 2007-06-30 Pf Medicament Nova anti IGF-IR protitelesa in njihova uporaba
FR2834991B1 (fr) 2002-01-18 2004-12-31 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2834990A1 (fr) 2002-01-18 2003-07-25 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2003223661A1 (en) 2002-04-15 2003-11-03 Rigel Pharmaceuticals, Inc. Methods of assaying for cell cycle modulators
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
AU2003231554A1 (en) 2002-04-30 2003-11-17 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP1506286B1 (en) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
GB0212303D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
WO2004007673A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal gene expression patterns
US20040142381A1 (en) * 2002-07-31 2004-07-22 Hubbard Stevan R. Methods for designing IGF1 receptor modulators for therapeutics
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
US20030138430A1 (en) * 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP2007524566A (ja) 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ レセプターとリガンドの間の相互作用の調節の方法
PL378812A1 (pl) * 2003-02-13 2006-05-29 Pfizer Products Inc. Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
DE602004029581D1 (de) 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper
DE10348391B3 (de) * 2003-10-17 2004-12-23 Beru Ag Verfahren zum Glühen einer Glühkerze für einen Dieselmotor
US7326567B2 (en) * 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1796711A2 (en) * 2004-04-22 2007-06-20 Oregon Health and Science University Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
EP1761281A1 (en) 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
KR20080019733A (ko) * 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
KR20070120156A (ko) * 2005-04-15 2007-12-21 이뮤노젠 아이엔씨 종양에서 이종 또는 혼성 세포 집단의 제거 방법
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007093008A1 (en) 2006-02-17 2007-08-23 Adelaide Research & Innovation Pty Ltd Antibodies to insulin-like growth factor i receptor
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker

Similar Documents

Publication Publication Date Title
JP2011157397A5 (https=)
TWI821474B (zh) Ｃｄ３抗體及其藥物用途
JP2021514664A5 (https=)
JP2021534762A5 (https=)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
CN112969476B (zh) 多特异性蛋白分子
JP7249696B2 (ja) 抗ｃｌｄｎ抗体並びにその医薬組成物および検出方法
JP2020528750A5 (https=)
CN106749677B (zh) 一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
JP2024531409A5 (https=)
JP2019531084A5 (https=)
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
JP2005538701A5 (https=)
JP2013527762A5 (https=)
WO2012076066A1 (en) Anti-ror1 antibodies and uses thereof
JP2021528047A5 (https=)
JP2020536507A5 (https=)
JP2021528400A5 (https=)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
CN104829728A (zh) 一种双特异性抗体her2xcd3的构建及应用
CN109160949B (zh) 一种鼠抗人pd-1单克隆抗体及应用
US11021538B2 (en) Bispecific coupled antibody, preparation method and application thereof
CN117229398A (zh) 抗cldn18.2抗体、其药物组合物及用途
JP2009544574A5 (https=)
JP7407742B2 (ja) Ｇａｓｐ－１顆粒を標的とする結合性タンパク質及びキメラ抗原受容体ｔ細胞並びにそれらの使用